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Summary  24 
Hospital-based surveillance was conducted at two widely separated regions in Myanmar during 25 
the 2015 dengue epidemic. Acute phase serum samples were collected from 332 clinically 26 
diagnosed dengue patients during the peak season of dengue cases. Viremia levels were 27 
measured by quantitative real-time PCR and plaque assays using FcγRIIA-expressing and non 28 
FcγRIIA-expressing BHK cells to specifically determine the infectious virus particles. By 29 
serology and molecular techniques, 280/332 (84.3%) were confirmed as Dengue patients. All 30 
four serotypes of dengue virus (DENV) were isolated from among 104 laboratory-confirmed 31 
patients including two cases infected with two DENV serotypes. High percentage of primary 32 
infection was noted among the severe dengue patients. Patients with primary infection or 33 
DENV IgM negative demonstrated significantly higher viral loads but there was no significant 34 
difference among the severity groups. Viremia levels among dengue patients were notably high 35 
for a long period which was assumed to support the spread of the virus by the mosquito vector 36 
during epidemic. Phylogenetic analyses of the envelope gene of the epidemic strains revealed 37 
close similarity with the strains previously isolated in Myanmar and neighboring countries. 38 
DENV-1 dominated the epidemic in 2015 and the serotype (except DENV-3) and genotype 39 










Dengue viruses (DENV) belong to the genus Flavivirus, the members of which are positive-47 
sense single-stranded RNA viruses and can be transmitted to humans by the bite of infected 48 
mosquitoes, mainly Aedes aegypti. Infection with DENV can result in asymptomatic 49 
manifestation or can cause a wide range of clinical manifestations from mild dengue (DEN) to 50 
severe infection [1].  The estimated DENV infections per year is 390 million worldwide and 51 
the high incidence makes an economic and social burden not only to developing countries but 52 
also to high and middle income countries such as Singapore [2-4]. 53 
The first DENV outbreak in Myanmar was in 1970 and epidemic outbreaks occur at two to 54 
three year intervals [5-9]. The number of reported DEN patients has been increasing during the 55 
last four decades and the highest peak was in 2015. Moreover, two consecutive outbreaks 56 
occurred within the last three years (2013-2015) [7]. Virus evolution (genotype or serotype 57 
shifting) is an important factor for causing outbreaks [10].To observe the viral evolution, the 58 
molecular study for understanding the circulating DENV serotypes and genotypes during 59 
epidemic is essential. Thus, sentinel site surveillance was conducted to understand the 60 
molecular epidemiology of DENV at different geographical and environmental areas (central 61 
dry zone versus coastal area) in Myanmar.  62 
Moreover, the previous outbreaks in Myanmar reported that the percentage of primary 63 
infection among severe cases were high [7, 8].We assumed that the high viremia level would 64 
be an important factor for causing severe DEN among Myanmar children with primary 65 
infection. But, according to literature reviews, the association between the viremia level and 66 
disease severity is still controversial and remains an inconclusive issue. Some researchers 67 




13] but other reports showed there is no association [14, 15]. Therefore, this study also focused 69 
to investigate the association between viremia level and disease severity in Myanmar DEN 70 
patients. Thus, to prove the above hypothesis, viral loads levels were measured by quantitative 71 
real time PCR method (qRT-PCR) and plaque forming assay using FcγRIIA-expressing and 72 
non FcγIIA-expressing BHK-21 cells. In this study, we focused on counting infectious particles 73 
by Fcγ-expressing BHK cells-based plaque assay because previous studies only focused on 74 
counting genome copies by qRT-PCR results which might not provide an accurate picture of 75 
the virus infectivity. In addition, characterization of the clinical manifestations and virological 76 
patterns of infection among DEN patients and the molecular epidemiology of DENV 77 
circulating in Myanmar during the 2015 outbreak could be of help in elucidating our hypothesis. 78 
Methods 79 
Study Areas 80 
The areas selected for the study were two dengue epidemic sites in Myanmar: Mandalay and 81 
Myeik.  Mandalay, an inland city, is located in a central dry zone of Upper Myanmar and close 82 
to the border with China, India and Bangladesh.  Myeik, a coastal area in the Mergui 83 
archipelago, is located in Lower Myanmar and near the border with Thailand (Supplementary 84 
Figure S-1). The mean annual rainfall (central dry zone versus coastal region: 700 mm versus 85 
5,500 mm) and seasonal temperature generally vary in the two sites (source: Department of 86 
Metrology and Hydrology, Ministry of Transport). 87 
Patients and sample collection 88 
Patients included in the study were those clinically diagnosed to have DEN infection according 89 
to WHO 2009 guideline [1]. Laboratory confirmation was done by virus isolation or by 90 




Severity of the disease was determined by the combined clinical symptoms and laboratory data 92 
according to WHO 2009 guideline [1]. 93 
Patients were recruited at two hospitals in Mandalay (550-bedded Mandalay Children Hospital 94 
and Mandalay General Hospital) and one hospital in Myeik (Myeik Public 95 
Hospital).  Collection of blood samples was done between July and August during the peak of 96 
the 2015 outbreak. Samples were kept at -80˚C and all experiments except complete blood 97 
count (CBC) were conducted at the Department of Virology, Institute of Tropical Medicine, 98 
Nagasaki University, Japan. CBC was done using ABX-Pentra 60 Automated Haematology 99 
Analyzer (Horiba Medical, France) in Myanmar. 100 
Serological tests 101 
In-house DENV specific IgM capture ELISA and indirect anti-flavivirus IgG ELISA were done 102 
on all serum samples following the procedure described previously [15, 16]. NS1 antigen from 103 
serum samples was detected by using Dengue NS1 Rapid Test Kit (Inbios, Internationals, Inc, 104 
USA) following the instruction of the manufacturer [16]. Patients were confirmed to have 105 
primary or secondary infection based on the results of the in-house anti-flavivirus IgG ELISA 106 
which was previously validated as a test similar to the WHO recommended Haemagglutination 107 
Inhibition test for differentiating primary and secondary DENV infection [7, 8, 17]. Primary 108 
infection in clinically diagnosed DEN patients was determined if the acute serum samples were 109 
positive for DENV isolation or for DENV IgM or NS-1 Antigen but with no detectable anti-110 
flavivirus IgG [18]. Secondary infection was determined in patients if the acute or convalescent 111 
phase serum samples had an anti-flavivirus IgG antibody titers ≥ 52,000. If patients had an 112 
acute phase serum samples only with an IgG titers ≥ 3000 but < 52,000, they were considered 113 
to have an undetermined type of infection [7, 8, 17].   114 




Serum samples at 10µl volume each were inoculated to Aedes albopictus clone mosquito cell 116 
line (C6/36 E2) for dengue virus isolation [19]. After 7 days of incubation at 28⁰C, infected 117 
culture fluids (ICF) were harvested and viral RNA was extracted by using Viral RNA Mini kit 118 
(QIAGEN, Hilden, Germany).  Screening for the presence of DENV was done by Prime Script 119 
TM one step RT-PCR Kit (Takara Bio Inc., Shiga, Japan) using universal flavivirus primer.  One 120 
step RT-PCR method using serotype-specific DENV primers was done to determine the 121 
serotypes of the virus isolates [20, 21]. 122 
Quantification of viremia by using BHK and FcγRIIA-expressing BHK cells 123 
The viral loads were quantified only from patient serum samples positive for virus isolation. 124 
Plaque assay. The experiments were performed according to the previous reports with 125 
modification [18, 22]. Both FcγRIIA-expressing BHK-21 and non FcγRIIA-expressing BHK-126 
21 cells were prepared in separate 24-well cell culture plates. Each serum sample was diluted 127 
ten-fold from 101 to 106 with Eagle’s minimal essential medium. A 100 µl volume of diluted 128 
serum was inoculated to 90-100% confluent cells in each well and the plates were incubated 129 
for one hour at 37⁰C incubator with 5% CO2. A 500 µl of maintenance medium including 1% 130 
methylcellulose were then laid over the cells. After 5 days, the plates were fixed with 4% 131 
paraformaldehyde and stained with crystal violet. Plaques were counted and the amount of 132 
virus particles in plaque forming units per ml (PFU/ml) was calculated by using the formula: 133 
[mean number of plaques per well x dilution factor] /inoculum volume. In this assay, two 134 
independent experimental set-ups were done and the serum samples at different dilutions were 135 
inoculated onto cells in duplicates. 136 
qRT-PCR.  Viral RNA was directly extracted from patient serum by using the same kit to 137 
extract RNA from infected culture fluid. To determine the genome copies of virus, 5 µl of RNA 138 




Taq man reagents following the protocol from a previous report and the mean results were 140 
reported as genome copies [23]. 141 
Gene sequencing and phylogenetic analysis  142 
The whole envelope protein (E) gene of all the isolated virus strains were amplified by specific 143 
primer sets [7].  Sequence was performed by using the BigDye Terminator 3.1 ver and analyzed 144 
by ABI PrismTM Capillary Sequencer 3130-Avant Genetic Analyzer. The nucleotide sequences 145 
were aligned by Clustal X, version 2.0 software. With the Maximum Likelihood method using 146 
PHYML 3.0.1, phylogenetic trees were constructed based on the full E gene region of the virus 147 
strains isolated from this study and from previously isolated strains in Myanmar and its 148 
neighboring countries and from the other different regions of the world. The substitution model 149 
was selected by jmodeltest-2.1.7 and GTR + l + G was chosen as the model. Trees were drawn 150 
by Fig tree software, version 1.4.2 (FigTree) [22]. The DNA fragments encoding the full length 151 
of E protein of DENV were submitted to GenBank (accession numbers from KX357894 to 152 
KX357999). 153 
Ethics statement  154 
The protocol for this study was reviewed by the Ethics Review Committee on Medical 155 
Research Involving Human Subjects, Department of Medical Research, Republic of the Union 156 
of Myanmar and approved as indicated in the letter numbered 63/Ethics 2015. Written 157 
informed consent was obtained from the adult patients or the parents/guardian of the paediatric 158 
patients.   159 
Statistical analysis 160 
Data analysis was done by using the IBM.SPSS software 20.0 version. Mean values between 161 




compared using one way ANOVA test, and then post hoc test was performed to detect the 163 
significant difference among different populations. Non-parametric test was used to compare 164 
median values. Chi-square test was done to compare the categorical variables. P value <0.05 165 
was assumed as significant in this study.   166 
Results 167 
Characteristics of the laboratory confirmed DEN cases  168 
A total of 332 clinically diagnosed DEN patients with single acute phase serum samples was 169 
investigated from two study sites in Myanmar. From among them, 280 (84.3%) were laboratory 170 
confirmed to have DENV infection. Out of the confirmed cases, 47 (16.8%) belonged to the 171 
category of DEN without warning signs and 184 (65.7%) with warning signs while 49 (17.5%) 172 
were with severe DEN. There were 137 (48.9%) males and 143 (51.1%) females. The median 173 
age in years for the patients without warning signs was 4.0 (2.3 –7.5) and for the patients 174 
presenting with warning signs and severe DEN were 7.0 (4.0 -10.0) and 6.0 (4.3-9.0), 175 
respectively. The median age for the patients without warning signs was lower than the other 176 
two groups (P value-0.02).  177 
Of the DEN confirmed cases, 228 (81.4%) patients were positive for IgM antibody against 178 
DENV. Serum samples only from 235 patients were checked for NS-1 antigen test due to the 179 
limitation of test kit, and 165 showed positive results. Based on the anti-flavivirus IgG titers, 180 
121 (43.2%) cases were classified as primary infection, 111 (39.6%) cases as secondary 181 
infection and 48 (17.2%) cases as undetermined type of infection. For the patients with primary 182 
infection, the median age was 6.0 years (3.0-9.0) and for those with  secondary infection was 183 
7.0 years (5.0 – 10.5). The distribution of primary and secondary infection in different age 184 




Thirty out of 47 patients without warning signs (63.8%), and 12 of 49 patients (24.5%) with 186 
severe DEN had primary infection. The number of severe cases with primary infection was 187 
quite high. The number of dengue patients with warning signs were highest in all age groups 188 
(Fig-1B). 189 
 190 
Clinical and laboratory features of patients with isolated DENV  191 
At least one of four DENV serotypes was isolated from each of the 104 patients in this study. 192 
A comparative analysis on demographic data, laboratory parameters, type of infection, clinical 193 
manifestations and infecting serotypes was done among these patients with DENV isolates 194 
and was shown in Supplementary Table S-1. There was no significant difference in the age, 195 
gender, type of infection and white blood cell count (WBC) among the different severity 196 
groups of patients. However, platelet counts and hematocrit values were significantly different 197 
among the three groups (P<0.05). There was also no differences in the clinical manifestations 198 
(haematemesis, abdominal pain, liver size) between dengue with warning sign groups and 199 
severe dengue (Supplementary Table S-1).  200 
Association of serum viremia level and antibody response 201 
In general, it was noted that the DENV load level of serum samples quantified by using Fcγ-202 
bearing cells were higher than ordinary BHK cells and qRT-PCR method (Fig-2).  Viraemia 203 
levels were higher for the patients negative for DENV IgM antibody in comparison with those 204 
from the patients positive for DENV IgM antibody (Fig-2A). This finding was consistently 205 
significant in all the methods used–plaque assay using either type of BHK cells and qRT-PCR. 206 
The viraemia levels were noticeably high up to day 6 from the onset of fever (Fig-2B) and the 207 




day 5 of infection (Fig-2C). The virus titers were also compared between cases with primary 209 
and secondary infection and the virus titers were found significantly higher in patients with 210 
primary infection (P < 0.05) (Fig-2D). 211 
Comparison of viremia levels among patients exhibiting different levels of severity of 212 
DENV infection 213 
The mean viral loads among the three groups of patients grouped according to the levels of 214 
disease severity did not differ significantly (P>0.05) with respect to day of fever (Fig-3) or to 215 
specific serotype (DENV-1, -2, -4) excluding the two cases of mixed infection (Table-1). 216 
Distribution of DENV isolates in the two study areas   217 
A total of 106 virus strains were isolated from 104 DEN patients with 66 viral strains from 218 
patients in Mandalay and 40 from patients in Myeik.  In Mandalay, 50 strains (75.8%) of the 219 
isolated strains were DENV-1, 15 strains (22.7%) DENV-2 and one strain (1.5%) DENV-4. 220 
On the other hand, in Myeik, 26 strains (65%) were DENV-1, nine strains (22.5%) DENV-2, 221 
one strain (2.5%) DENV-3, four strains (10%) DENV-4. There were two instances with mixed 222 
infection of two serotypes. One instance (DENV-1 and DENV-4) was from Mandalay, Upper 223 
Myanmar and the other (DENV-1 and DENV-2) from Myeik, Lower Myanmar. 224 
Phylogenetic analysis  225 
The phylogenetic tree based on the full coding region of E protein of DENV-1 strains from 226 
both study areas in Myanmar shows that all the strains belonged to Genotype 1 (Fig-4). The 227 
50 strains from Upper Myanmar were sub-clustered into three distinct lineages but the 26 228 
strains from Lower Myanmar fell within one lineage. Most strains had 99% nucleotide 229 




related from the strains circulating in China, Thailand, Sri Lanka and the strains previously 231 
isolated in Myanmar. Moreover, there was no association between the disease severity and 232 
specific clade of DENV-1 based on the phylogenetic analysis. 233 
All the isolated DENV-2 from the two study areas fell under Asian I genotype and formed two 234 
lineages.  Most of the strains were closely similar to the strains circulating in Thailand, China 235 
and Myanmar strains and had 99% nucleotide similarity to the previously isolated strains in 236 
Myanmar (Fig-5). The only DENV-3 isolate from this study and which came from Lower 237 
Myanmar belonged to the genotype III.  This strain was closely related to the strains circulating 238 
in Thailand, Laos, Cambodia and Vietnam (Supplementary Figure S-2). The four DENV-4 239 
strains from Lower Myanmar and the one strain from Upper Myanmar belonged to genotype I 240 
(Supplementary Figure-S-3). The strains were similar to the strains from Myanmar and 241 
Thailand.  242 
Discussion 243 
In Myanmar, the regular incidence of hospitalized DEN patients is about 7,000-9,000 cases per 244 
year and can reach more than 15,000 per year during an outbreak according to the hospital 245 
statistics of the Ministry of Health and Sports.  During the DEN epidemics in 2009, 2013, and 246 
2015, the incidence rates were 24,285, 20,255 and 42,913 cases, respectively. The total 247 
reported cases for 2015 was comparable to the total cases during the last five years from 2010 248 
to 2014 indicating that the 2015 outbreak was the biggest to this date. Although the incidence 249 
rate in 2015 was very high, the mortality rate (0.32%) decreased in numbers compared to the 250 
previous years. This reduction in mortality rate could be due to early diagnosis, effective 251 
treatment and timely referral system in Myanmar [7] which were made possible through 252 




for dengue. In addition are the capacity building for the medical officers for the early 254 
recognition of early warning signs and the political commitment of the government for the 255 
technical and material support (source: Ministry of Health and Sports, Myanmar).  256 
In the present study, DENV-1 was the most prevalent serotype in the two study sites in 257 
Myanmar during the 2015 outbreak. Although the samples were collected from two study areas 258 
with different geographical and environmental background, the DENV serotype and genotype 259 
distribution pattern was similar in the two regions. The DENV circulating during this outbreak 260 
were heterogeneous having similarities not only from the strains previously isolated in 261 
Myanmar but also to the strains from neighboring countries. Not only virus factor but also 262 
demographic data (age, sex) of laboratory confirmed DEN patients in this study was similar to 263 
the results of previous surveillance data in Myanmar [7, 8]. For clinical manifestation, there 264 
were no specific clinical signs and symptoms associated with each serotype of DENV. The 265 
number of patients with specific serotypes were limited, hence it was difficult to make 266 
conclusion about the association of clinical presentation with respect to serotype. 267 
Haematocrit values differed among the three groups of patients with different disease severity 268 
and were highest in patients with severe dengue due to plasma leakage. Platelet count was 269 
lowest in patients with severe dengue, followed by those with warning signs. The reduced 270 
platelet count could be due to bone marrow suppression of platelet production or increased 271 
destruction. According to WHO guidelines, these two laboratory markers are  important 272 
parameters for predicting severe dengue [1] which were confirmed in this study. 273 
A noticeably high number of primary infection was noted among severe DEN cases in this 274 
study. To this date, the prevalence of severe DEN during primary infection has been high in 275 
Myanmar. Some South East Asian countries (Philippines, Indonesia and Thailand,) also 276 
reported the high percentage of severe dengue with primary infection [7]. Many factors are 277 




(genetic background, underlying diseases, nutritional status, immune response) could be 279 
involved in the pathogenesis of severe DEN with primary infection [8]. Among 12 severe 280 
dengue patients with primary infection in this study, six patients (50%) were infected with 281 
DENV-1 and three patients with DENV-2, however the infecting serotype of the last three 282 
patients were unknown due to the failure of virus isolation. The virulence factors of the 283 
circulating DENV (genotype and phenotype) could be involved in the pathogenesis of severe 284 
dengue [8]. The study from Singapore found that DENV-1 (genotype 1) and DENV-2 285 
(Cosmopolitian genotype) can cause severe dengue than other serotypes or genotypes [23].  286 
Similarly, DENV-1 (Genotype -1) and DENV-2 were dominant in this outbreak but DENV-2 287 
strains were of the Asian-1 genotype.  Furthermore, some mutant virus strains could change to 288 
virulent form and could cause severe disease without ADE phenomenon [24].  289 
It was also observed in this study that the viremia level was significantly higher among patients 290 
with primary infection (Fig2-D). One study  reported that the  peak viremia level was up to 3 291 
days and gradually decreased 2.2 log10 per day [25]. In this study, the viral loads were 292 
consistently high during primary infection up to day 5 of fever (Fig2-C), but no significant 293 
difference was observed in the viral loads among the three different severity groups. Analysis 294 
done based on or regardless of the infecting serotype showed no differences between these 295 
groups. (Table-1). Therefore, not only high viremia level but also many factors could be 296 
involved in the high rate of severe dengue with primary infection in Myanmar. 297 
In this study, viremia levels were also higher among patients negative for IgM antibody 298 
compared to the positive ones (p value <0.05). The presence of DENV specific IgM antibody 299 
could influence the viremia level of the patients in this study. Based on the literature review, 300 




[26]. Moreover. one study also proved that the viremia level decreased when the IgM antibody 302 
appeared in blood and this made the isolation of the virus difficult [27].  303 
Generally, qRT-PCR results expressed the number of biological molecules i.e the copy number 304 
of virus genome but not the infectious potential of the virus. To determine the biological 305 
infectious properties, plaque assays should be done [28]. Results of qRT-PCR could not be 306 
equated with the results of plaque assays because the presence of defective non-infectious 307 
particles detected by qRT-PCR could not be detected by plaque assays and thus the results 308 
could be misleading [29]. There were previous studies on the comparison of viraemia level 309 
with the different degrees of clinical severity based only on qRT-PCR method [30, 31]. 310 
Therefore, this study included the plaque assay method in addition to qRT-PCR method to 311 
assess the correlation of viremia and disease severity. In this study, there were comparable 312 
results between these two diagnostic methods. The samples collected in this study were fresh 313 
and there was no repeated freeze and thawing procedures that occurred.  The viremia level of 314 
Fcγ-expressing cells were higher in this study because the presence of Fcγ receptor plays an 315 
important role in DENV pathogenesis such as virus initiation and replication stage of DENV 316 
infection [32]. 317 
The high plasma viremia level of DEN patients is an important marker to be able to spread 318 
DENV from infected human to mosquitoes during an outbreak. The viremia level above the 319 
mosquito infectious dose [MID50]] could play as a source of infection for spreading the disease 320 
[33]. Most DENV-1 and DENV-2 patients from our study had high viremia level above the 321 
MID50 when compared to the study conducted in Vietnam [33]. Aedes aegypti mosquitoes 322 
feeding on viremia patients can spread the virus to another person after at least 11 days of 323 




observed up to day 6 of fever. Thus, the presence of dengue patients that were highly viremia 325 
for a long span of time could be the source of sustaining the 2015 large epidemic in Myanmar.   326 
According to the phylogenetic tree analysis based on the full coding region of the E protein, 327 
the genotypes of the circulating DENV serotypes in both study areas were not different. All 328 
DENV-1 isolates were genotype I with three distinct clades but the viral strains from Myeik 329 
sub-clustered to one unique clade. The DENV-1 strains from Mandalay in 2013 belonged to 330 
Genotype-1 and were distributed into three distinct clades [7]. The DENV-1 isolates in 2015 331 
belonged to the same three clades as in 2013.  332 
Although previous studies reported that both Asian I and Cosmopolitan genotypes of DENV-333 
2 were circulating in Myanmar, only Asian I genotype with two distinct clades was isolated in 334 
the 2013 [7] and 2015 outbreaks. Similarly in DENV-3, two genotypes (II and III) were 335 
previously circulating in Myanmar [35] but only Genotype III was isolated in 2015. For 336 
DENV-4, only Genotype I was found circulating in Myanmar. These studies proved that 337 
different DENV serotypes and genotypes (except for DENV-4) have been co-circulating in 338 
Myanmar [7]. 339 
In conclusion, all four DENV serotypes were confirmed to be concurrently circulating and 340 
causing epidemic in Myanmar with DENV-1 as the most dominant serotype. Additionally, the 341 
number of severe DEN patients with primary infection were still high during the 2015 outbreak. 342 
Patients with primary infection demonstrated high level of viremia but there was no association 343 
between the viral loads and disease severity. The high viral load with a long duration among 344 
the viremia DEN patients could perhaps serve as the increased source of infection to support 345 
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Table -1. Viral loads of patients grouped according to infecting DENV serotype and disease severity 1 
Infecting serotype and 
disease severity  
Number of 
Patients 
Real time PCR 
(log 10 genome copies) 
Plaque forming Unit  (log 10 PFU/ml) 
 N  P-Value FcγIIA-expressing 
BHK cells 
P value BHK cells P value 
DENV 1,2,3,and 4*        
DEN without warning signs 27 5.49±1.11 0.93 5.73±1.59 0.56 5.32±1.35 0.62 
DEN with warning signs 65 5.48±1.21  5.85±1.47  5.26±1.35  
Severe Dengue 12 5.36±0.93  5.33±1.85  4.88±1.60  
DENV-1  
 
       
DEN without warning signs 17 5.37±1.12 0.93 5.62±1.60 0.36 5.37±1.14 0.39 
DEN with warning signs 48 5.47±1.26  5.92±1.42  5.39±1.31  
Severe Dengue 9 5.33±1.05  5.14±2.06  4.70±1.78  
DENV-2 
 
       
DEN without warning signs 8 5.71±1.21 0.92 5.90±1.83 0.99 5.16±1.50 0.93 
DEN with warning signs 12 5.41±1.11  5.90±1.56  5.08±1.46  
Severe Dengue 3 5.42±0.48  5.87±1.14  5.40±0.91  
DENV-4  
 
       
DEN without warning signs 1 6.16±0.00 0.88 6.70±0.00 0.48 5.60±0.00 0.16 
DEN with warning signs 3 5.98±1.00  5.33±1.31  4.73±0.35  
*Patients were grouped together according to the levels of disease severity regardless of the infecting serotype 2 






Fig. 1. Distribution of the occurrence of (a) primary and secondary infection, and (b) disease severity at different levels 3 







Fig. 2. Comparison of viremia levels by plaque assay (FcγRIIA-expressing and non-expressing BHK cells) and/or by 3 
qRT–PCR. (a) DENV IgM-positive vs. DENV IgM-negative patients, (b) according to the day of fever of patients with 4 
isolated DENV, (c) day of fever among primary infection cases, and (d) primary vs. secondary infection. *Student’s t test 5 





Fig. 3. Comparison of viral load levels among patients with isolated DENV and exhibiting different levels of severity of 2 
infection. (a) FcγRIIA-expressing BHK cells-based plaque assay, (b) FcγRIIA-non-expressing BHK cells-based plaque 3 









Fig. 4. DENV-1 phylogenetic tree. Phylogenetic tree was constructed based on the whole nucleotide sequences of the E 1 
protein gene of DENV-1 showing the relationship of 82 strains from different sources including 28 strains of DENV-1 2 
isolated during the 2015 epidemic in Myanmar. The representative strains of each genotype obtained from Genbank are 3 






Fig. 5. DENV-2 phylogenetic tree. Phylogenetic tree was constructed based on the whole nucleotide sequences of the E protein 2 
gene of DENV-2 showing the relationship of 79 strains from different sources including 24 strains of DENV-2 isolated during 3 
the 2015 epidemic in Myanmar. The representative strains of each genotype obtained from Genbank are named by country 4 
origin, strain name, year of isolation and GenBank accession number. *UpperMyanmar; **LowerMyanmar. 5 
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Supplementary Table S-1 Characteristics of patients with isolated DENV 
























(5.6 – 8.5) 
0.43 
Sex      
   Male 53 (51%) 11 33 9 0.14 
   Female 
 
51 (49%) 16 32 3  
Laboratory 
parameters 
     
   WBCb             5.85 ± 2.46 6.51 ± 2.63 5.70 ± 2.18 5.19 ± 3.28 0.22 
   Platelets b 156.68±78.08 211.37±89.87 147.32±61.06 84.33±52.28 <0.001 
   Hematocrit c 35.88±8.07 31.90±13.72 37.13±4.17 38.08± .05 
 
0.01 
Type of Infection      
   Primary  82 /104 
(78.9%) 
24/82 (29.3%) 49/82  
(59.8%) 
9/82 (11.0%) 0.60 
   Secondary  12/104 
(11.5%) 




2/12 (16.7%)  






1/10 (10.0%)  
Clinical     NA 
   Coffee ground  
   Vomiting 
12 0 7 5  
   Pleural  
   Effusion 
1 0 0 1  
   Rash 5 0 5 0  
   Vomiting 33 0 26 7  
   Abdominal  
   Pain 
24 0 20 4  
  Hepatomegaly 35 0 28 7  
   Epistaxis 34 0 26 8  
Serotypes      
   DENV-1 74 17 48 9 NA 
   DENV-2 23 8 12 3  
   DENV-3 1 0 1 0  
   DENV-4 4 1 3 0  
   Mixed    
   Infection* 
2 1 1 0  
 
a Age in Years- Median (Inter quartile Range, IQR) 
b WBC and Thrombocyte count; number of cells x 109/L in Mean ± SD 
c Hematocrit level in Mean % ± SD 
*DENV-1 and DENV-2, DENV-1 and DENV-4 





Supplementary Fig.S-1 Map of the study area 
The study area from Upper Myanmar showed with (■) and the study area from lower Myanmar showed 
with (       ) 
 
 
Supplementary Fig S-2. DENV-3 Phylogenetic tree.  
Phylogenetic tree was constructed based on the whole nucleotide sequences of the E protein gene of 
DENV-3 showing the relationship of 48 strains from different sources including one strain of DENV-3 
isolated during the 2015 epidemic in Myanmar. The representative strains of each genotype obtained 
from Genbank are named by country origin, strain name, year of isolation and GenBank accession 








Supplementary Fig S-3. DENV-4 Phylogenetic tree.  
Phylogenetic tree was constructed based on the whole nucleotide sequences of the E protein gene of 
DENV-4 showing the relationship of 50 strains from different sources including 5 strains of DENV-4 
isolated during 2015 epidemic in Myanmar. The representative strains of each genotype obtained from 
Genbank are named by country origin, strain name, year of isolation and GenBank accession number. * 
Upper Myanmar ** Lower Myanmar 
